Probe into White House, PhRMA Dealings on Reform Law Continues

An ongoing federal probe indicates there was a deal between the White House and the Pharmaceutical Research and Manufacturers of America that bound both entities to certain commitments before Congress passed the healthcare reform law.

Under the leadership of Rep. Cliff Stearns (R-Fla.), the House Energy and Commerce Subcommittee on Oversight and Investigations sent a memo (PDF) Wednesday to Republican members of the full panel to provide an update on the subcommittee's investigation. The inquiry aims to answer the following: Did the Obama administration and outside stakeholders make deals that exchanged policy outcomes for public support of the law; if so, who made such deals; was Congress left out of the discussions; what issues were negotiated; and what, if anything, did the White House gain in the arrangement.

Read the full story: